![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessCardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis
Prevalence of cardiac and vascular fibrosis in patients with Idiopathic Pulmonary Fibrosis (IPF) has not been extensively evaluated.
-
Article
Open AccessTwo-year cardio-pulmonary follow-up after severe COVID-19: a prospective study
Short- and medium-term cardio-pulmonary sequelae after COVID-19 have been extensively studied. However, studies with longer follow-ups are required. This study aims to identify and characterise cardio-pulmonar...
-
Article
Open AccessThe usual Interstitial pneumonia pattern in autoimmune rheumatic diseases
Usual Interstitial Pneumonia (UIP) is characterized by progression of lung parenchyma that may be observed in various autoimmune rheumatic diseases (ARDs), including rheumatoid arthritis and connective tissue ...
-
Article
Open AccessConcurrent features of sarcoidosis and hypersensitivity pneumonitis in two patients exposed to fungal antigens
Sarcoidosis and hypersensitivity pneumonitis (HP) are two distinct clinical entities that share granulomatous inflammation, although each of them has specific clinical, radiologic and pathologic profiles. Coex...
-
Article
Open AccessEffectiveness and economic impact of Dupilumab in asthma: a population-based cohort study
Severe asthma is burdened by relevant socio-economic and clinical impact. Randomized controlled trials on Dupilumab showed efficacy and a good safety profile, but post-market studies are needed.
-
Article
Open AccessSarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach
Sarcopenia gained importance in the evaluation of patients with chronic respiratory diseases, including idiopathic pulmonary fibrosis (IPF), since it may impact negatively on clinical outcomes.
-
Article
Open AccessOne-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study
Long-term pulmonary sequelae following hospitalization for SARS-CoV-2 pneumonia is largely unclear. The aim of this study was to identify and characterise pulmonary sequelae caused by SARS-CoV-2 pneumonia at 1...
-
Article
Interstitial pneumonia associated with autoimmune diseases: a possible mimicker of SARS-CoV-2 pneumonia
-
Article
Open AccessIdiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated median survival time of 3–5 years after diagnosis. This condition occurs primarily in elderly subjects, and epidemiol...
-
Article
Open AccessManagement of acute respiratory failure in interstitial lung diseases: overview and clinical insights
Interstitial lung diseases (ILDs) are a heterogeneous group of diseases characterized by widespread fibrotic and inflammatory abnormalities of the lung. Respiratory failure is a common complication in advanced...
-
Article
Open AccessSerum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study
The role and relationship between pro- and anti-inflammatory cytokines represents one of the least studied aspects of the pathogenesis of community-acquired pneumonia (CAP). The aim of the present study was to...
-
Article
Hospital Admission Decision for Patients with Community-Acquired Pneumonia
Where to treat patients is probably the single most important decision in the management of community-acquired pneumonia (CAP), with a substantial impact on both patients’ outcomes and health-care costs. Sever...